Mumbai Angels, a premium platform for private investments, has invested in Mestastop Solutions, a cancer metastasis drug discovery and predictive diagnostics-focused biotech based out of Bengaluru. Mestastop Solutions has secured investment from Mumbai Angels for the second time since its initial backing in 2020. The recent funding round participation from 92 angel investors and Malpani Ventures.

Mestastop Solutions plans to leverage the funds to generate a PoC (proof of concept) around the novel target and position two approved drugs for clinical trials to explore delaying metastasis for primary tumour patients in an adjuvant setting.

Nandini Mansinghka, Co-Founder and CEO of Mumbai Angels said," Mestastop is working on a noble cause to develop anti-metastatic drugs. Our continued investment in the company indicates our confidence and belief in Mestastop Solutions' potential to make a meaningful impact."

Arnab Roy Chowdhury, Founder Mestastop Solutions said, "With this investment, we intend to realise our dream of offering unique, tech-backed strategies to develop anti-metastatic drugs that focus on delaying metastasis causing the spread of cancer." 

Mestastop is a deep-tech startup that focuses on the functional properties of patient primary tumour samples to identify distinct phenotypes that can act as markers of metastatic cells. Over the past five years, Mestastop has integrated wet lab biology and machine learning algorithms to develop three proprietary platforms to unravel metastasis biology.

The company has filed for multiple patents in the USA and Europe and currently has two ongoing European collaborations and three Indian collaborations.